How Does It Work for MASH? Rezdiffra belongs to a class of medicines called thyroid hormone receptor-beta (THR-β) agonists. In the liver, Rezdiffra attaches to the THR-β receptors. This ...

Rezdiffra (resmetirom) is a prescription drug used to help treat a specific kind of liver disease in certain situations. Rezdiffra comes as an oral tablet. Rezdiffra is used to treat nonalcoholic ...

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal ...

The results further emphasize the efficacy of their thyroid hormone receptor (THR)-β agonist, Rezdiffra, in treating NASH. Rezdiffra is an innovative, once-daily medication that targets key ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

The company’s top line comprises only its product revenues. Madrigal’s commercial portfolio has one marketed drug, Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist.

The price you pay for Rezdiffra may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable ...